The combination of the R263K and T66I resistance substitutions in HIV-1 integrase is incompatible with high-level viral replication and the development of high-level drug resistance

Journal of Virology

Volumn 89, Issue 22, 2015, Pages 11269-11274

  Liang, Jiaming ^a,b   Mesplède, Thibault ^a   Oliveira, Maureen ^a   Anstett, Kaitlin ^a,c   Wainberg, Mark A ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE; RALTEGRAVIR; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR; P31 INTEGRASE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; QUINOLONE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; MUTATIONAL ANALYSIS; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PURIFICATION; SITE DIRECTED MUTAGENESIS; SUBSTITUTION THERAPY; VIRUS INFECTIVITY; VIRUS REPLICATION; AMINO ACID SUBSTITUTION; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; HIV INFECTIONS; TUMOR CELL LINE; VIROLOGY;

AMINO ACID SUBSTITUTION; CELL LINE, TUMOR; DRUG RESISTANCE, VIRAL; HEK293 CELLS; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; QUINOLONES; RALTEGRAVIR POTASSIUM; VIRUS REPLICATION;

EID: 84945897017     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01881-15     Document Type: Article

References (22)

1. Mesplede T, Wainberg MA. 2013. Integrase strand transfer inhibitors in HIV therapy. Infect Dis Ther 2:83-93. http://dx.doi.org/10.1007/s40121-013-0020-8.
2. Mesplede T, Wainberg MA. 2014. Is resistance to dolutegravir possible when this drug is used in first-line therapy? Viruses 6:3377-3385. http://dx.doi.org/10.3390/v6093377.
3. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. 2011. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 203:1204-1214. http://dx.doi.org/10.1093/infdis/jir025.
4. Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, Poizot-Martin I, Richmond G, Soriano V, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J. 2013. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis 207:740-748. http://dx.doi.org/10.1093/infdis/jis750.
5. Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, Molina JM, Chas J, Durant J, Moreno S, Doroana M, Ait-Khaled M, Huang J, Min S, Song I, Vavro C, Nichols G, Yeo JM. 2014. Dolutegravir in antiretroviral-experienced patients with raltegravir-and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 210:354-362. http://dx.doi.org/10.1093/infdis/jiu051.
6. Akil B, Blick G, Hagins DP, Ramgopal MN, Richmond GJ, Samuel RM, Givens N, Vavro C, Song IH, Wynne B, Ait-Khaled M. 2015. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study. Antivir Ther 20:343-348. http://dx.doi.org/10.3851/IMP2878.
7. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S. 2013. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 382:700-708. http://dx.doi.org/10.1016/S0140-6736(13)61221-0.
8. Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA. 2013. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 10: 22. http://dx.doi.org/10.1186/1742-4690-10-22.
9. Wares M, Mesplede T, Quashie PK, Osman N, Han Y, Wainberg MA. 2014. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology 11:7. http://dx.doi.org/10.1186/1742-4690-11-7.
10. Mesplede T, Osman N, Wares M, Quashie PK, Hassounah S, Anstett K, Han Y, Singhroy DN, Wainberg MA. 2014. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. J Antimicrob Chemother 69:2733-2740. http://dx.doi.org/10.1093/jac/dku199.
11. Lataillade M, Chiarella J, Kozal MJ. 2007. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 12:563-570.
12. Singhroy DN, Wainberg MA, Mesplede T. 2015. Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity. Antimicrob Agents Chemother 59:2882-2885. http://dx.doi.org/10.1128/AAC.05181-14.
13. Oliveira M, Mesplede T, Quashie PK, Moisi D, Wainberg MA. 2014. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS 28: 813-819. http://dx.doi.org/10.1097/QAD.0000000000000199.
14. Cutillas V, Mesplede T, Anstett K, Hassounah S, Wainberg MA. 2015. The R262K substitution combined with H51Y in HIV-1 subtype B integrase confers low-level resistance against dolutegravir. Antimicrob Agents Chemother 59:310-316. http://dx.doi.org/10.1128/AAC.04274-14.
15. Quashie PK, Mesplede T, Han YS, Veres T, Osman N, Hassounah S, Sloan RD, Xu HT, Wainberg MA. 2013. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob Agents Chemother 57:6223-6235. http://dx.doi.org/10.1128/AAC.01835-13.
16. Han YS, Quashie P, Mesplede T, Xu H, Mekhssian K, Fenwick C, Wainberg MA. 2012. A high-throughput assay for HIV-1 integrase 3'-processing activity using time-resolved fluorescence. J Virol Methods 184: 34-40. http://dx.doi.org/10.1016/j.jviromet.2012.05.003.
17. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T. 2011. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 55:813-821. http://dx.doi.org/10.1128/AAC.01209-10.
18. White K, Kulkarni R, Miller MD. 2015. Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients. J Antimicrob Chemother 70:2632-2638. http://dx.doi.org/10.1093/jac/dkv149.
19. Hurt CB, Sebastian J, Hicks CB, Eron JJ. 2014. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis 58:423-431. http://dx.doi.org/10.1093/cid/cit697.
20. Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. 2012. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 86:2696-2705. http://dx.doi.org/10.1128/JVI.06591-11.
21. Margot NA, Hluhanich RM, Jones GS, Andreatta KN, Tsiang M, McColl DJ, White KL, Miller MD. 2012. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res 93:288-296. http://dx.doi.org/10.1016/j.antiviral.2011.12.008.
22. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 359:355-365. http://dx.doi.org/10.1056/NEJMoa0708978.